English
Back
Download
Log in to access Online Inquiry
Back to the Top

NEWS

Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study


Biodesix (Nasdaq: BDSX) announced new data presentation at CHEST 2024 Annual Meeting and launch of a complementary clinical study. The presentation will showcase the use of Nodify Lung® Nodule Risk Assessment in over 35,000 patients in real-world settings. Dr. Kathryn Long will present findings on reclassification rates for lung cancer risk, highlighting how the tests help clarify diagnostic plans.


Additionally, Biodesix introduced the CLARIFY study, a retrospective chart review of up to 4,000 patients, aimed at confirming the performance of Nodify CDT® and Nodify XL2® tests in diverse patient subgroups. This study will expand evidence supporting Nodify Lung testing's validation and utility.

CEO Scott Hutton emphasized the impact of Nodify Lung testing on lung nodule risk characterization over the past four years. The CHEST conference will also feature a presentation on patient impact and case studies by Drs. Sonali Sethi and D. Kyle Hogarth.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
5862 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    6056Followers
    70Following
    65KVisitors
    Follow
    Discussing
    Trump 2.0 countdown: What's the next big opportunity in the markets?
    Trump is gearing up for a return to the political stage, and his "America First" tariff policies, along with his stance on cryptocurrency an Show More